This page contains information about Novo Nordisk products.



A smooth experience starts with devices that are easy to use

FlexPro® — put simplicity in their hands

Easy to use

The FlexPro® pens are easy to use. The medication is prefilled and preloaded into each pen so that the patient does not need to mix, load or change a cartridge.1 The FlexPro® pens’ compact size and ergonomic design make them easy to hold and an easy-to-push button delivers dose.1,2 Quick setup and administration make FlexPro® easy to learn.3

Device Features of FlexPro<sup>®</sup> prefilled growth hormone pens

Easy to dose

FlexPro® pens provide flexibility in dosing with three different size pens each with different dosing increments and maximum dosage:

  • 5 mg/1.5 mL pen (0.025 mg increments, 2 mg maximum dose)
  • 10 mg/1.5 mL pen (0.05 mg increments, 4 mg maximum dose)
  • 15 mg/1.5 mL pen (0.1 mg increments, 8 mg maximum dose)
FlexPro<sup>®</sup> Pens

FlexPro® pens have many helpful dosing features including an easy-to-read, contrasting background dose window and an end-of-dose clicking sound to alert the patient when the medication has left the pen. The FlexPro® pens make a different clicking sound when dialing forward and backward to clearly indicate dialing direction.4
Learn more

Storage flexibility*

FlexPro® 5 mg/1.5 mL and 10 mg/1.5 mL pens can be left at room temperature after initial use.3
Learn more

* All Norditropin® products must be refrigerated prior to first use.
Do not freeze. After initial use, FlexPro® 5 mg/1.5 mL and 10 mg/1.5 mL delivery pens can either be stored outside of the refrigerator (at up to 77°F) for use within 3 weeks or in the refrigerator (between 36°F and 46°F) for use within 4 weeks. The FlexPro® 15 mg/1.5 mL delivery pen must always be refrigerated (between 36°F and 46°F)—both prior to and after the initial injection—for use within 4 weeks.

The Norditropin® Device Pledge

Norditropin<sup>®</sup> device pledge

If, after filling three paid prescriptions for Norditropin®, your patient is not satisfied with his or her pen, Novo Nordisk will pay up to $125 of the patient’s first copay for a competing medication.

* † Norditropin® Device Pledge Terms and Conditions
Patients must be new to therapy with Norditropin®, but could have previously taken a competing product. Patients receiving copay assistance with NordiSure are eligible. Patients must provide proof of three paid months of therapy with Norditropin® in compliance with their treatment plan, proof of purchase of a competing product, and a letter stating the reason why they are dissatisfied. Offer expires 60 days after the date of the last script filled by a pharmacy. Patients cannot be receiving copay assistance or a free product from the manufacturer of a competing product. Novo Nordisk reserves the right to rescind, revoke, or amend this offer without notice at any time. This offer is not valid for individuals who are covered by Medicaid or Medicare and in certain states. Not valid for residents of Massachusetts. Offer good only in the United States.


  1. Data on file. PDS290 pen-injector for Norditropin® SimpleXx® container closure system: comparison to Norditropin NordiFlex®. Princeton, NJ: Novo Nordisk Inc; 2009.
  2. Data on file. PDS290-UT03-2008: Usability test in children/adolescents with growth hormone deficiency evaluating ease of handling when injecting and general acceptance of the Norditropin® PDS290pen. Princeton, NJ: Novo Nordisk Inc; 2009.
  3. Norditropin® prescribing information. Princeton, NJ: Novo Nordisk Inc; 2010.
  4. Data on file. Quality overall summary. Norditropin FlexPro® prefilled pen. NJ: Novo Nordisk Inc; 2009.